Chandler Kramer
Gerontology · Eugene, ORNPI 1326730615
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $743 and has fallen 54.5% since, to $338 in 2025.
Across 40 payments — averaging $35.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$260
- Viiv Healthcare Company$214
- Actelion Pharmaceuticals US, Inc.$203
- AstraZeneca$149
- Merz North America, Inc.$108
- Regeneron Healthcare Solutions, Inc.$96
- plus $387 from 11 others
What the payments were for
- Food & beverage$1,32894%
- Education$896%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 8 | $260 |
| Viiv Healthcare Company | 5 | $214 |
| Actelion Pharmaceuticals US, Inc. | 2 | $203 |
| AstraZeneca | 3 | $149 |
| Merz North America, Inc. | 1 | $108 |
| Regeneron Healthcare Solutions, Inc. | 1 | $96 |
| Intra-sana Laboratories | 4 | $79 |
| Astellas Pharma US Inc | 2 | $58 |
| Pfizer | 2 | $48 |
| Antares Pharma, Inc. | 3 | $46 |
| Amgen | 2 | $36 |
| Halozyme Inc | 2 | $31 |
| AbbVie | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Cordis US CORP. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,417 in reported general payments places this provider in the 80th percentile of 53 gerontology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 21 | $21,787 |
| FarxigaDapagliflozin Propanediol | 32 | $21,118 |
| JardianceEmpagliflozin | 13 | $11,048 |
| Testosterone Cypionate | 30 | $1,333 |
| Testosterone | 14 | $1,094 |
| Trazodone Hcl | 17 | $657 |
| Ezetimibe | 14 | $596 |
| Rosuvastatin Calcium | 52 | $593 |
| ProgesteroneProgesterone, Micronized | 17 | $571 |
| Spironolactone | 19 | $457 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $405 |
| Levothyroxine Sodium | 24 | $367 |
| Fenofibrate | 13 | $364 |
| Estradiol | 15 | $342 |
| Fluticasone Propionate | 17 | $299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $13 | $21,78721 claims |
| AstraZenecaFarxiga | $149 | $21,11832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 53 gerontology providers in Oregon.
Other gerontology in Eugene
- Jennifer GardnerEugene$5K
- Charity CapurasEugene$1K
- Lauren BrownPortland$32K
- Alexia DudoitBend$14K
- Kimberly FlowersPortland$5K
- Molly DavisPortland$3K
- Jennifer TurnerPortland$3K
- Timothy HiltonSalem$2K
- Jennifer GoodrichPortland$2K
- Rhezarie Mae AgtarapPortland$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.